Back to results
US 9,427,455 B2Granted
Use of the pat nanopeptide in the treatment of autoimmune diseases
AssigneeCLL Pharma
InventorsJamal Temsamani, Claude Laruelle
Life of this patent
Estimating the term…
Abstract
The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.
Claims10
A method of treating an autoimmune disease, comprising administering an effective amount of the PAT nonapeptide,
- (SEQ ID NO:
- 1)
- EAKSQGGSD,
- or a pharmaceutically acceptable salt thereof, to a person in need thereof.
1 more element
Dependencies are inferred from the claim text.